HIDRAdenitis Suppurativa and HEART Disease
Launched by HERLEV AND GENTOFTE HOSPITAL · Aug 4, 2023
Trial Information
Current as of July 24, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how certain heart health markers and advanced heart imaging techniques relate to the severity of a skin condition called hidradenitis suppurativa (HS). The researchers want to find out if these markers can help predict heart diseases in people who have HS. They are looking for 250 participants who are at least 18 years old and have been diagnosed with HS.
If you join the study, you will undergo tests to measure your heart health and the severity of your HS. The researchers are currently recruiting participants, and they welcome individuals of all genders. However, if someone cannot cooperate with the study or cannot understand the consent form, they will not be eligible to participate. This trial aims to provide valuable insights into the connection between HS and heart health, which could help improve care for patients in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age ≥ 18 years
- • Diagnosis of HS
- Exclusion Criteria:
- • Patients unable to cooperate to the study and/or study examinations
- • Patients unable to understand and sign informed consent
About Herlev And Gentofte Hospital
Herlev and Gentofte Hospital, a leading healthcare institution in Denmark, is dedicated to advancing medical research and patient care through innovative clinical trials. As a prominent sponsor, the hospital focuses on a wide range of therapeutic areas, leveraging its multidisciplinary expertise and state-of-the-art facilities to facilitate rigorous scientific investigation. Committed to enhancing treatment outcomes and improving patient quality of life, Herlev and Gentofte Hospital collaborates with academic institutions and industry partners to foster groundbreaking discoveries and translate research findings into clinical practice.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hellerup, Copenhagen, Denmark
Patients applied
Trial Officials
Tor Biering-Sørensen, MD PhD MPH
Study Director
Department of Cardiology, Herlev and Gentofte University Hospital, University of Copenhagen
Claus Zachariae, MD DMSc
Study Director
Department of Dermato-Allergology, Herlev and Gentofte University Hospital, University of Copenhagen
Lone Skov, MD PhD DMSc
Study Director
Department of Dermato-Allergology, Herlev and Gentofte University Hospital, University of Copenhagen
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported